Stocks Weekly Recommnedation by Moneymaker Indore

Weekly Wrap: - Market registered modest gains in what was a volatile trading week. Sentiment were upbeat as retirement fund manager Employees Provident Fund Organization (EPFO) entered the stock market through exchange-traded funds (ETFs) from Thursday, 6 August 2015, four months after it decided to invest in equities.

Meanwhile, the Reserve Bank of India (RBI) kept its benchmark lending rate viz. the repo rate unchanged at 7.25% after a monetary policy review on Tuesday, 4 August 2015. RBI Governor Dr. Raghuram G. Rajan left the door open for monetary policy easing.

The Sensex rose 121.83 points or 0.43% to settle at 28,236.39 last week. The Nifty rose 31.75 points or 0.37% to settle at 8,564.60.

The Q1 June 2015 corporate earnings season concludes next week.

Soybean may trade upward on less monsoon forecast according to IMD

According to IMD, as of 28 July, monsoon rains in India were 3% below normal. It said rains in July and August could be less than normal. Kharif sowing progress - area of 14.30 million hectares were covered by oil seeds as of 24 July including 10.48 million hectares of Soybean crop. Soybean may consolidate sideways with a bullish bias.

Moneymaker Research PVT. LTD. Guide to all Investors, You can Sell NCDEX Soyabean for Long term targets 2900. you can hold it near at October month. 

Why broken Sun Pharma shares, brokerage houses Also Reduced Target

Sun Pharma stock is seeing a huge drop in the morning. Shares of the company declined by 12 percent at Rs 833 has come. Market analysts say that Sun Pharma profit warning is issued for the current fiscal. Pressure on the company's stock. After the news, Sun Pharma giant brokerage houses also have slashed their target.

Why is Sun Pharma stock decline

Sun Pharma profit warning is issued for the current fiscal. The company says it will raise the cost of the merger of Ranbaxy, which may have put pressure on margins.On the margins may be pressured. Since fiscal year 2016 growth will improve. Consolidation in the coming years, while the company will break from business.

Sun Pharma Managing Director Dilip Sanghvi Analysts also said, "We will see the reality of adverse news that may come in the coming days to be ready to handle themselves Sanghvi Hoga. Akikrn process with the FDA issue 'Financial Year after 2016 'will have gone. He indicated that exposure to loss under the products prepared at the option of the other sites can be adopted.

Brokerage House deductible target

> Makwayri Sun Pharma, target reduced from Rs 1100 to Rs 1000 has been fixed. In the financial year 2016-17 EPS estimates by 15 per cent and 10 per cent cut.

> Bank of America Merrill Lynch downgraded Sun Pharma target of Rs 950 to Rs 1063 has been fixed. EPS estimates for the financial year 2016-17 and 20 per cent in the 30% cut.

> Barclays Ikwlvet on Sun Pharma has set a target of Rs 922 while maintaining the rating.

> Morgan Stanley's overweight rating on Sun Pharma reduced from Rs 1010 to Rs 1047 while maintaining the target is fixed.

> Jefrij purchase on the Sun Pharma has set a target of Rs 1100 while keeping opinion. According to him, raising concerns that delays in Halol plant.